Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

British drugmaker GSK plans to acquire US biotech firm IDRx for $1.15 billion, focusing on innovative tumour treatments.